新生血管性年龄相关性黄斑变性眼内注射法瑞西单抗、布西珠单抗与阿柏西普2 mg后30分钟眼部血流变化的比较
回顾性观察性病例系列纳入45例新生血管性年龄相关性黄斑变性患者的45只眼,用激光散斑血流图比较玻璃体腔注射法瑞西单抗、布西珠单抗或阿柏西普2 mg前与注射后30分钟的视盘及脉络膜血流。三组注射后30分钟视盘MV与脉络膜MBR均显著下降,三组视盘MV下降率无显著差异,布西珠单抗组脉络膜MBR下降幅度大于阿柏西普组。
要点
- 三组注射后30分钟视盘MV与脉络膜MBR均较注射前显著下降。
- 三组视盘MV下降率无显著差异。
- 布西珠单抗组脉络膜MBR下降幅度大于阿柏西普组(P=0.027)。
核心结论
- 法瑞西单抗、布西珠单抗或阿柏西普2 mg治疗后30分钟,新生血管性年龄相关性黄斑变性眼眼部血流显著下降。
- 布西珠单抗治疗眼脉络膜血流下降幅度显著大于阿柏西普治疗眼。
研究设计与样本
- 回顾性观察性病例系列,纳入45例日本新生血管性年龄相关性黄斑变性患者的45只眼,分别接受玻璃体腔法瑞西单抗、布西珠单抗或阿柏西普2 mg注射。
- 使用激光散斑血流图分析注射前与注射后30分钟视盘MV及脉络膜平均模糊率。
主要发现
- 注射后30分钟视盘MV平均下降:法瑞西单抗组12.0%±15.3%、布西珠单抗组9.5%±7.9%、阿柏西普组10.4%±11.9%。
- 注射后30分钟脉络膜平均模糊率平均下降:法瑞西单抗组9.7%±8.8%、布西珠单抗组18.2%±12.9%、阿柏西普组6.0%±7.7%。
- 三组视盘MV下降率无显著差异;脉络膜平均模糊率下降幅度布西珠单抗组大于阿柏西普组(P=0.027),法瑞西单抗 vs 布西珠单抗 P=0.161,法瑞西单抗 vs 阿柏西普 P=0.631。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate ocular blood flow before and 30 minutes postinjection of antivascular endothelial growth factor agents in eyes with neovascular age-related macular degeneration and to compare the reduction rates of ocular blood flow among three groups: intravitreal faricimab injections (faricimab-treated), intravitreal brolucizumab injections (brolucizumab-treated), and intravitreal aflibercept 2 mg injections (aflibercept-treated). METHODS: This retrospective observational case series included 45 eyes of 45 Japanese patients with neovascular age-related macular degeneration treated with faricimab, brolucizumab, or aflibercept 2 mg. Ocular blood flow at the optic nerve head (ONH MV) and the choroid (choroid mean blur rate) was analyzed before and 30 minutes after injections using laser speckle flowgraphy. RESULTS: The mean optic nerve head MV and choroid mean blur rate decreased significantly 30 minutes postinjection by 12.0% ± 15.3% and 9.7% ± 8.8% in the faricimab-treated group, 9.5% ± 7.9% and 18.2% ± 12.9% in the brolucizumab-treated group, and 10.4% ± 11.9% and 6.0% ± 7.7% in the aflibercept-treated group. There were no significant differences in the reduction rates of optic nerve head MV among the three groups. However, the brolucizumab-treated group showed a greater reduction in choroid mean blur rate than the aflibercept-treated group (faricimab vs. brolucizumab: P = 0.161; faricimab vs. aflibercept: P = 0.631; brolucizumab vs. aflibercept: P = 0.027). CONCLUSION: Ocular blood flow significantly decreased 30 minutes postinjection in faricimab-treated, brolucizumab-treated, or aflibercept-treated eyes with neovascular age-related macular degeneration. Brolucizumab-treated eyes showed a significantly greater reduction in choroidal blood flow than aflibercept-treated eyes.
引用
- Kato N, Haruta M, Matsuo Y, et al. COMPARISON OF OCULAR BLOOD FLOW CHANGES AT 30 MINUTES AFTER INTRAVITREAL INJECTION OF FARICIMAB, BROLUCIZUMAB, AND AFLIBERCEPT 2 mg FOR NEOVASCULAR AGE-RELATED MACULAR. Retina. 2025. PMID: 40577636. doi:10.1097/IAE.0000000000004561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。